Dimeric and Multimeric FVIIa Compounds
The present invention relates to dimeric or multimeric FVIIa compounds comprising at least two FVIIa polypeptides covalently connected such as to retain the intrinsic catalytic activity of the FVIIa polypeptides.
1 . A multimeric FVIIa compound comprising at least two FVIIa polypeptides covalently linked, wherein said compound exhibits FVIIa catalytic activity.
2 . (canceled)
3 . The compound according to claim 1 , wherein said compound has an increased biological activity as compared to the biological activity of the constituent FVIIa polypeptides.
4 . The compound according to claim 1 , wherein two FVIIa polypeptides are covalently connected to form a dimeric FVIIa compound.
5 . (canceled)
6 . The compound according to claim 1 , wherein said FVIIa polypeptides covalently connected are identical FVIIa polypeptides.
7 . The compound according to claim 1 , wherein at least two different FVIIa polypeptides are covalently connected.
8 . The compound according to claim 1 , wherein said multimeric FVIIa compound comprises a linker between the constituent FVIIa polypeptides.
9 . The compound according to claim 8 , wherein said linker has the structure that results from a reaction involving a bivalent cysteine reactive PEG.
10 . The compound according to claim 8 , wherein said linker has the structure that results from a reaction involving maleimide-PEG-maleimide.
11 . The compound according to claim 10 , wherein said maleimide-PEG-maleimide is selected from the group consisting of maleimide-PEG2kD-maleimide, maleimide-PEG3.4kD-maleimide, maleimide-PEG5kD-maleimide, maleimide-PEG10kD-maleimide, and maleimide-PEG20kD-maleimide.
12 . The compound according to claim 8 , wherein said linker comprises an amino acid sequence.
13 . The compound according to claims claim 1 , wherein said at least two FVIIa polypeptides are covalently connected via free amines in said FVIIa polypeptides.
14 . The compound according to claim 1 , wherein said at least two FVIIa polypeptides are covalently connected via natural or engineered glycans attached to said FVIIa polypeptides.
15 . (canceled)
16 . The compound according to claim 1 , wherein said FVIIa polypeptide is selected from the group consisting of: FVIIa 407C, a FVIIa 407C variant; FVIIa P406C; a FVIIa P406C variant; FVIIa R396C; a FVIIa R396C variant; FVIIa Q250C; and a FVIIa Q250C variant
17 .- 22 . (canceled)
23 . The compound according claim 1 , wherein said FVIIa polypeptide is a FVIIa variant which comprises substitutions selected from the group consisting of L305V, L305V/M306D/D309S, L3051, L305T, F374P, V158T/M298Q, V158D/E296V/M298Q, K337A, M298Q, V158D/M298Q, L305V/K337A, V158D/E296V/M298Q/L305V, V158D/E296V/M298Q/K337A, V158D/E296V/M298Q/L305V/K337A, K157A, E296V, E296V/M298Q, V158D/E296V, V158D/M298K, S336G, L305V/K337A, L305V/V158D, L305V/E296V, L305V/M298Q, L305V/V158T, L305V/K337A/V158T, L305V/K337A/M298Q, L305V/K337A/E296V, L305V/K337A/V158D, L305V/V158D/M298Q, L305V/V158D/E296V, L305V/V158T/M298Q, L305V/V158T/E296V, L305V/E296V/M298Q, L305V/V158D/E296V/M298Q, L305V/V158T/E296V/M298Q, L305V/V158T/K337A/M298Q, L305V/V158T/E296V/K337A, L305V/V158D/K337A/M298Q, L305V/V158D/E296V/K337A, L305V/V158D/E296V/M298Q/K337A, L305V/V158T/E296V/M298Q/K337A, S314E/K316H, S314E/K316Q, S314E/L305V, S314E/K337A, S314E/V158D, S314E/E296V, S314E/M298Q, S314E/V158T, K316H/L305V, K316H/K337A, K316H/V158D, K316H/E296V, K316H/M298Q, K316H/V158T, K316Q/L305V, K316Q/K337A, K316Q/V158D, K316Q/E296V, K316Q/M298Q, K316Q/V158T, S314E/L305V/K337A, S314E/L305V/V158D, S314E/L305V/E296V, S314E/L305V/M298Q, S314E/L305V/V158T, S314E/L305V/K337A/V158T, S314E/L305V/K337A/M298Q, S314E/L305V/K337A/E296V, S314E/L305V/K337A/V158D, S314E/L305V/V158D/M298Q, S314E/L305V/V158D/E296V, S314E/L305V/V158T/M298Q, S314E/L305V/V158T/E296V, S314E/L305V/E296V/M298Q, S314E/L305V/V158D/E296V/M298Q, S314E/L305V/V158T/E296V/M298Q, S314E/L305V/V158T/K337A/M298Q, S314E/L305V/V158T/E296V/K337A, S314E/L305V/V158D/K337A/M298Q, S314E/L305V/V158D/E296V/K337A, S314E/L305V/V158D/E296V/M298Q/K337A, S314E/L305V/V158T/E296V/M298Q/K337A, K316H/L305V/K337A, K316H/L305V/V158D, K316H/L305V/E296V, K316H/L305V/M298Q, K316H/L305V/V158T, K316H/L305V/K337A/V158T, K316H/L305V/K337A/M298Q, K316H/L305V/K337A/E296V, K316H/L305V/K337A/V158D, K316H/L305V/V158D/M298Q, K316H/L305V/V158D/E296V, K316H/L305V/V158T/M298Q, K316H/L305V/V158T/E296V, K316H/L305V/E296V/M298Q, K316H/L305V/V158D/E296V/M298Q, K316H/L305V/V158T/E296V/M298Q, K316H/L305V/V158T/K337A/M298Q, K316H/L305V/V158T/E296V/K337A, K316H/L305V/V158D/K337A/M298Q, K316H/L305V/V158D/E296V/K337A, K316H/L305V/V158D/E296V/M298Q/K337A, K316H/L305V/V158T/E296V/M298Q/K337A, K316Q/L305V/K337A, K316Q/L305V/V158D, K316Q/L305V/E296V, K316Q/L305V/M298Q, K316Q/L305V/V158T, K316Q/L305V/K337A/V158T, K316Q/L305V/K337A/M298Q, K316Q/L305V/K337A/E296V, K316Q/L305V/K337A/V158D, K316Q/L305V/V158D/M298Q, K316Q/L305V/V158D/E296V, K316Q/L305V/V158T/M298Q, K316Q/L305V/V158T/E296V, K316Q/L305V/E296V/M298Q, K316Q/L305V/V158D/E296V/M298Q, K316Q/L305V/V158T/E296V/M298Q, K316Q/L305V/V158T/K337A/M298Q, K316Q/L305V/V158T/E296V/K337A, K316Q/L305V/V158D/K337A/M298Q, K316Q/L305V/V158D/E296V/K337A, K316Q/L305V/V158D/E296V/M298Q/K337A, K316Q/L305V/V158T/E296V/M298Q/K337A, and the 407C variants thereof.
24 . The compound according to claim 1 , wherein at least one of said FVIIa polypeptides is PEGylated.
25 .- 27 . (canceled)
28 . A method for preparation of a compound according to claim 1 , said method comprising the steps of:
a) synthesis and purification of said FVIIa polypeptides;
b) synthesis of said compound by coupling said FVIIa polypeptides;
c) isolation of said multimeric FVIIa compound.
29 .- 30 . (canceled)
31 . A method of treating a bleeding disorder, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1 .